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Background: Platelets are instrumental to primary haemostasis; in addition, as they are central to endothelium
vascular repair, they play a role in physiological inflammation. Platelets have also been demonstrated to be key
players in innate immunity and inflammation, expressing Toll-like receptors (TLRs) to sense microbial infection and
initiate inflammatory responses. They are equipped to decipher distinct signals, to use alternate pathways of signalling
through a complete signalosome, despite their lack of a nucleus, and to adjust the innate immune response appropriately
for pathogens exhibiting different types of ‘danger’ signals. Previous work has described the two main LPS isoforms-TLR4
activation pathways in purified platelets. However, the precise mechanism of TLR4 signalling in platelets is not completely
unravelled, especially how this signalling may occur since platelets do not express CD14, the TLR4 pathophysiological
companion for LPS sensing. Thus, we investigated from what source the CD14 molecules required for TLR4 signalling in
platelets could come.
Results: Here we show that CD14, required for optimal response to LPS stimulation, is obtained from plasma, but used
with restrictive regulation. These data add to the body of evidence that platelets are closer to regulatory cells than to
first line defenders. The readout of our experiments is the canonical secreted cytokine-like protein, soluble (s)CD40L, a
molecule that is central in physiology and pathology and that is abundantly secreted by platelets from the alpha-granules
upon stimulation.
Conclusions: We show that sCD14 from plasma contributes to LPS/TLR4 signalling in platelets to allow significant release
of soluble CD40L, thereby elucidating the mechanism of LPS-induced platelet responses and providing new insights for
reducing LPS toxicity in the circulation.
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The principal role of platelets is to control primary
haemostasis. Physiologically, they patrol the large vascu-
lar system, detect endothelium insults and repair vascu-
lar damage to prevent leakage [1] To this end, platelets
are equipped with molecular detectors that sense mole-
cules abnormally exposed in the vessels, indicating* Correspondence: olivier.garraud@univ-st-etienne.fr
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unless otherwise stated.alterations, i.e., danger [2]. It has been postulated that
tissue repair, beginning with danger exclusion and heal-
ing, is important for the initiation of inflammation, espe-
cially subsequent to ‘danger’ signalling [3], indicating a
possible role for platelets in this process [4]. Supporting
this hypothesis is the discovery that platelets intervene
throughout the spectrum of tissue physiology and path-
ology/inflammation: this has been exemplified in trans-
fusion hazards [5] but also, importantly, in organ
inflammatory pathology [6,7].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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can engulf infectious pathogens, though the nature of
binding and endocytosis as well as the outcome of the
pathogen within the platelet is still largely unknown.
There is now a large body of evidence that platelets are
intimately linked with infection. This arises from clinical
observations of bacteraemia and sepsis, situations where
there is usually a platelet drop and a risk of bleeding,
and from experimental animal models. Numerous fac-
tors have been considered, outlining the complexity of
this physiopathology [8].
Common to all platelet functions in vivo, including
primary haemostasis, physiological inflammation and
pathogen sensing, and leading to a wide range of out-
comes, from the possible clearance of pathogens to acute
pathology, is the discrete secretion of factors. There are
three sources of platelet associated molecules: the alpha-
granules, the dense granules, and cleavage from mem-
branes. Platelet associated membrane molecules are
either endogenous, or absorbed from the environment
(principally the plasma) [9]. Platelets can also secrete
and re-internalize some of their products, making their
physiology much more complex than initially thought
[10]. Despite being non-nucleated, platelets can secrete
enormous amounts of cytokines and biological response
modifiers [1,4], depending on the nature of the stimuli
applied to the cells [11]. A call for a complete revisit of
the interactions between platelets and bacteria resulted
from reports that platelets express several types of
pathogen recognition receptors, including Toll-like recep-
tors (TLRs), both in human and mouse [12,13]. However,
there may be phenotypic and fundamental functional
differences between the expression of TLRs in mouse
versus human platelets. Furthermore, a signalosome was
described in platelets, with distinct signalling pathways,
through NF-κB activation [14,15].
In humans, platelets bind different types of Gram-
negative bacteria lipopolysaccharide (LPS) via membrane-
expressed TLR4, and can sense them differentially and
secrete discrete cytokine profiles [11,16]. In mice, al-
though there is clear evidence of LPS-TLR4 binding, sub-
sequent platelet activation and cytokine secretion remains
largely unclear. The question as to whether LPS-TLR4
binding can lead to the secretion of soluble CD40 ligand
(sCD40L), one of the major platelet-secreted factors, has
been recently addressed [17]; the possibility that genetic
polymorphisms explain the variations in affinity or inter-
actions with physiologically relevant molecules has been
raised.
However, another puzzling issue remains regarding
LPS-TLR4 binding and functioning: the interplay with
lipopolysaccharide binding protein (LBP) and CD14,
considered obligate partners of TLR4 for ligation of LPS.
This LPS-TLR4 signalling pathway has been dissected inthe monocyte system, which is extremely responsive to
LPS in both mouse and human systems [18]; but in con-
trast to monocytes, platelets do not express CD14 [19,20].
In the present study, we tested the hypothesis that hu-
man platelets can “borrow” soluble CD14 (sCD14) from
the plasma environment to activate membrane TLR4 sig-
nalling when exposed to LPS. These studies will increase
our understanding of how platelets function in path-
ology in infectious situations, and may lead to medical
interventions to prevent either the risk of bleeding or of




In accordance with French regulations (French Public
Health Code, Article L. 1223–3), platelets were obtained
from regular blood donors who signed a form, after be-
ing informed, indicating that they do not preclude the
use of their sample for medical research. Therefore, by
signing the donation form, blood donors give their con-
sent to take part in the study. Peripheral blood was col-
lected from healthy donors in endotoxin-free tubes with
3.2% sodium citrate (Vacutainer®, Becton Dickinson, San
Jose, CA, USA).Platelet-rich plasma (PRP) was prepared
by centrifugation at 150 × g for 12 min at 22°C. To assess
the quality of PRP preparation, leukocytes were also re-
covered at the interphase between the PRP and the red
cell pellet. Red cells contaminating the leukocyte suspen-
sion were removed with RBC lysis buffer, according to
the manufacturer’s instructions (eBioscience-Affimetrix,
Paris, France). For some experiments, platelets from
PRP were washed twice in PBS and resuspended in
Tyrode’s buffer (Sigma Aldrich, Lyon, France). The mean
leukocyte contamination of the PRP preparation was
0.18% of total cells. Analysis of cells showed no expres-
sion of CD14, CD15 and CD19 but a significant expres-
sion of CD3, suggesting that the contaminating cells
were mostly T cells and not monocytes.
Flow cytometry
CD63 expression, characteristic of activated platelets,
was measured in PRP by flow cytometry after gating on
CD41-positive events (CD41 is specifically expressed by
platelets) in the R5 region of the cytogram, as described
previously [11]. In the same way, CD3, CD14, CD15 and
CD19 lineage marker expression was assessed by im-
munostaining platelets with anti-human monoclonal
antibodies (mAbs). Leukocytes obtained after PRP prep-
aration and red cell lysis underwent the same staining
procedure and were analysed by flow cytometry in the
R6 region of the cytogram.
Phycoerythrin-conjugated mAbs against human CD63
(clone H5C6), allophycocyanin-conjugated mAbs anti-
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ate (FITC)-conjugated mAbs against human CD3 (clone
HIT3a), CD14 (clone M5E2), CD15 (clone HI 98) or
CD19 (clone SJ25CI) were purchased from BD Biosci-
ences (Le Pont de Claix, France). Positive events were
recorded by FACSCalibur (BD Biosciences) and analysed
with Cellquest Pro (BD Biosciences).
Platelet stimulation
Platelets (3 × 108) were stimulated for 30 min at room
temperature (RT) with ultrapure S-LPS from E. coli
0111: B4 (1–10 μg/ml; Cayla-Invivogen, Toulouse, France)
and recombinant CD14 (0.25 μg/ml; R&D Systems Europe
Ltd, Lille, France). Thrombin receptor activator peptide
(TRAP; 50 μg/ml; Sigma-Aldrich, Saint Quentin-Fallavier,
France) was used as a positive control. Platelets were
exposed to LPS for 30 min in the presence or absence of
mouse anti-human CD14 (clone 18D11; F(ab′)2; 20 μg/ml;
LifeSpan Biosciences, Inc., Seattle, WA, USA) or the
isotype control F(ab′)2 (clone 15H6; 20 μg/ml; LifeSpan
Biosciences).
sCD14 depletion in plasma
Anti-CD14 magnetic beads (Dynal, Life Technologies,
Saint Aubin, France) were used to capture sCD14 mole-
cules by negative selection according to the manufac-
turer’s protocols defined for immunoprecipitation.
Briefly, 1500 μl of Dynabeads were added to 450 μl of
PRP, incubated 1 hour at RT away from light and re-
moved from PRP using a magnetic particle concentrator.
Stimulation readout: platelet secretion of sCD40 ligand
The levels of sCD40L were measured in triplicate in
aliquots of unstimulated (control), TRAP- or TLR4
ligand-stimulated platelet supernatants by enzyme-
linked immunoabsorbent assay (ELISA; Abcys, Paris,
France); details have been provided previously [11,21].
Absorbance at 450 nm was measured by ELISA reader
(Multiskan EX; Labsystem, Helsinki, Finland).
Statistical analysis
The Wilcoxon paired test was used for comparison of
percentages of activated cells and of sCD40L secretion
in the different experiments. Values are expressed as




The PRP composition has been analysed for its purity
and representative pictures are shown in Figure 1. Of
particular note, we have focused on the CD14+ and
CD41+CD14+ populations (CD41 is a platelet marker).
Neither PRP nor washed cell preparations containsignificant CD14+-expressing cells; a 2% contamination
or expression appears constant in this series of experi-
ments (Figure 1E).
LPS-TLR4 activation studies: what role for exogenous
CD14?
Surface expression of CD63, a characteristic marker of
platelet activation, increased 7-fold upon the addition of
thrombin receptor activator peptide (TRAP) Ser-Phe-
Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe –
TRAP 14) (50 μg/ml; 30 min), which was used as an
activation control (Figure 2), and 5.5-fold upon exposure
to E. coli LPS for 30 min (≥3 μg/ml; Figure 2; P < 0.05).
This activation was observed in the presence of autolo-
gous plasma rich medium (sCD14 concentration: 24.90 ±
7.2 ng/ml), and was lost after platelet washing (residual
sCD14 concentration: 2.79 ± 1.47 ng/ml). Activation was
partially restored upon addition of exogenous, recombin-
ant CD14 (0.25 μg/ml; Figure 2), indicating that CD14 is
required to achieve activation by LPS through TLR4.
Consequence of platelet stimulation by LPS in the
presence or absence of sCD14 on sCD40L secretion
Exposure to TRAP (50 μg/ml; 30 min) increased sCD40L
secretion levels measured in the supernatant 2.7-fold
(Figure 3). Stimulation of platelets in their plasma en-
vironment with 2, 3 or 10 μg/ml LPS caused an in-
crease in sCD40L secretion of 1.62-, 1.82- or 2.63-fold,
respectively (Figure 3; P < 0.05). However, LPS when
used at a 1 μg/ml concentration failed to induce sCD40L
release by platelets.
To test the hypothesis that plasma-derived CD14 is in-
volved in LPS-TLR4-induced signalling leading to cytokine
secretion, we sought to use an anti-CD14 neutralizing anti-
body to block CD14. Anti-CD14 antibody (20 μg/ml) sig-
nificantly inhibited the augmentation of platelet sCD40L
secretion upon LPS stimulation (Figure 3).
As an additional control and to confirm the role of
plasma sCD14, we attempted to deplete sCD14 from
plasma before reusing it with autologous platelets for
LPS-TLR4 stimulation. To this end, we used anti-CD14
beads (Dynal, Life Technologies SAS, Saint Aubin, France).
However, despite a significant decrease of sCD14 in plasma
(not shown), this was not sufficient to test whether sCD14-
substantially depleted plasma renders the LPS-TLR4 un-
stable for ensuing signalling.
Discussion
It has been proposed that, to achieve activation by LPS,
CD14 association with platelet TLR4 is necessary [11].
This is the accepted model as described in the mono-
cyte, the dominant target of LPS sensing. Human den-
dritic cells also signal through this pathway. As platelets
are known to display functional TLR4 and react to LPS-
Figure 1 Flow cytometry analysis of CD3, CD14, CD15, CD19, and CD41 expression. Platelet-rich plasma (PRP) was prepared by centrifugating
peripheral blood from healthy donors and collecting in the upper phase. Leukocytes were also recovered at the interphase between the PRP and the
red cells. The contaminating red cells in the leukocyte suspension were removed by lysis. Platelets (A,D) and leukocytes (C,D) were stained for lineage
markers (CD3+ T cells, CD14+ monocytes, CD15+ neutrophils, CD19+ B cells and CD41+ platelets). Fluorescence analysis was gated on the R5 region for
PRP (A,B) and on R6 region of the cytogram for leukocytes (C,D). The presence of mononuclear cells in PRP preparation, although significant, was
clearly lower than in leukocyte preparation. The expression of CD14 on platelets from PRP was compared to that of washed platelets (E) after gating
on CD41-positive cells in the R5 region of the cytogram (data are expressed as percentage of CD expression ± SD; n = 10 experiments). Cytograms
shown (A,C) are representative of 10 independent experiments. *P < 0.05 (Wilcoxon paired test; platelets PRP vs. washed platelet suspension).
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express CD14, two plausible explanations can be consid-
ered: CD14 is indeed used by platelets but comes from
an external source, or TLR4/LBP/MD2 uses another
stabilizer for LPS sensing through TLR4. The present
study shows that sCD14 is necessary for platelet re-
sponses to LPS, particularly for the release of sCD40L,
the dominant platelet-secreted factor. Platelets are the
main source of sCD40L [25]. sCD40L is a master inflam-
matory cytokine in many systems, in particular for the
production of atheroma plaques and inflammation in
cardiovascular disease [1].
MD2 is a glycoprotein (20–25 kDa) expressed as both
a TLR4-bound complex on cell membranes and as an
active soluble form (sMD2) in the extracellular medium.
Soluble MD2 might increase and modulate steady state
levels of TLR4 on the surface of platelets and thus have
a role in innate immunity. Indeed, in eukaryotic cells,
LPS is transferred from CD14 to a heterodimeric protein
complex involving TLR4 and the accessory molecule
MD2, which forms a complete recognition site for LPS.
Lauer et al. [26] showed that LPS responsiveness in epi-
thelial cells can be controlled by circulating sMD2 that
gains access to extravascular spaces with endogenousTLR4 on the cell membrane. sMD2 does not appear to
modulate TLR4 gene expression directly and TLR4
mRNA levels did not significantly change in response to
incubation with sMD2. In accordance with Zhang G
et al., [22] we observed the expression of platelet MD2/
TLR4 as 9.87 ± 2.48%. Even though we observed a sig-
nificant (P < 0.05) increase after TRAP stimulation
(23.92 ± 6.67%), we did not observe significant modula-
tion after E. coli LPS incubation (6.58 ± 1.19%; data not
shown), nor CD14 on platelet membrane. This discrep-
ancy with the observation of Zhang et al. could be ex-
plained by the immunostaining technique used. Indeed,
while we stained platelets directly with a specific anti-
CD14 FITC-conjugated mAb (clone M5E2, BD Bio-
science) Zhang et al. used indirect immunostaining with
a mAb against human CD14 (clone UCH-M1) and a
FITC-conjugated mouse IgG.
We thus extended previous findings in showing the re-
quirement of sCD14 on platelets as well, but in contrast
to monocytes, platelets have to obtain it from the circu-
lation. This could be modelled by addition of recombin-
ant sCD14 to purified platelets exposed to LPS; and this
could be partly neutralized in the additional presence
of neutralizing Abs. Full activation or suppression of
Figure 3 Platelet sCD40L production and secretion. Platelets were unstimulated or stimulated with TRAP (50 μg/ml, 30 min at RT). Platelets
from platelet-rich plasma (PRP; black bars), or from platelet suspensions with added anti-human CD14 (clone 18D11 20 μg/ml; grey bars) or
isotype control (clone 15H6; white bars) were tested. Platelets were unstimulated or stimulated with E. coli LPS (1–10 μg/ml; 30 min at RT). Mean
sCD40L release was 1.2 ng/ml for unstimulated PRP and 1.5, 1.9, 2.2 and 3.1 ng/ml for LPS stimulation at concentrations of 1, 2, 3 and 10 μg/ml,
respectively. Data are expressed as fold increase of controls (± SD; n = 10 independent experiments). *P < 0.05 (Wilcoxon paired test; stimulated
vs. non-stimulated).
Figure 2 Flow cytometry analysis of CD63 expression on CD41+ platelets. Platelets were or stimulated or not with TRAP (50 μg/ml, 30 min
at RT). Platelets from platelet-rich plasma (PRP; black bars), washed (PBS) platelet suspensions (khaki bars) or washed (PBS) platelet suspensions
with added recombinant soluble CD14 (white bars) were tested. Platelets were then stimulated, or not, with E. coli LPS (1–10 μg/ml; 30 min at RT),
stained with allophycocyanin-conjugated anti-CD41 and phycoerythrin-conjugated anti-CD63 mAbs. Gating was made on the platelet population,
(R5 region according to FSC/SSC comparable to the Figure 1 cytogram). Double positive cells (CD41 + CD63+) were then measured. Data are
expressed as fold increase of controls (± SD; n = 10 independent experiments). *P < 0.05 (Wilcoxon paired test; stimulated vs. non-stimulated).
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ably because the reagents (sCD14, LPS, mAb) used do
not exactly mimic the endogenous folding and presenta-
tion of components where circulating platelets in the
blood flow encounter a LPS-harbouring live bacterium.
However, the model provides interesting clues to the
physiological functioning of platelets in septic inflamma-
tion. Despite many attempts, it was not possible to com-
pletely deplete sCD14 from plasma to provide further
confirmation of its requirement in LPS-TLR4 signalling.
Again, we propose that the folding, stability or even pur-
ity of the commercial reagent was not optimal to allow
any firm conclusion, but the partial demonstration
strengthens the proposed model. It cannot, however, be
ruled out that another, as-yet undefined, plasma factor is
used by platelets to mimic CD14 within the TLR4/LBP/
TLR2 complex.Conclusions
Dissecting the pathways of platelet physiology (primary
haemostasis), but also of physiopathology (sepsis, cardio-
vascular diseases, systemic inflammation, autoimmunity,
transfusion and transplantation pathology) [1,4,27] is
valuable for developing new drugs or treatments, taking
advantage of the benefits of platelets while removing
their deleterious effects, especially in patients with se-
vere conditions. The contribution of absorbed sCD14 on
platelets to complement LPS/TLR4 signalling and the
subsequent production of proinflammatory products in-
crease our understanding of platelet activation by bacter-
ial products, and may provide a new direction for
treatment of patients with bacteraemia/sepsis. Control-
ling LPS-induced responses by circulating platelets, as
well as leukocytes, could thus reduce systemic LPS tox-
icity and inflammation related to microbial invasion.
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